Strutture
Servizi
Contenuto della pagina - Torna all'inizio
- Cardiologia
- Clinica Medica, Trombosi ed emostasi, ematologia dell'anziano
- Endocrinologia e Oncologia Medica
- Farmacologia Clinica e Sperimentale
- Farmacologia e Tossicologia Cellulare e Molecolare
- Geriatria
- Malattie Infettive
- Medicina Interna e Gastroenterologia
- Medicina Interna, Malattie Vascolari e Metaboliche
- Nefrologia, Dialisi, Trapianto
- Pediatria e Adolescentologia
- Pneumologia
- Reumatologia
 | Giuseppe DerosaRicercatore Confermato Sede: Unità di Medicina Interna, Malattie Vascolari e metaboliche c/o Policlinico San Matteo |
| Telefono | + 39 0382 526217 |
| Fax | + 39 0382 526259 |
| giuseppe.derosa@unipv.it | |
| Curriculum | CURRICULUM DEROSA |
| Pubblicazioni | 1. Derosa G, Franzetti IG, Querci F, Carbone A, Ciccarelli L, Piccinni MN, Fogari E, Maffioli P. Exenatide plus metformin compared to metformin alone on β-cell function in patients with type 2 diabetes. Diabet Med 2012; 29(12): 1515-1523. Impact Factor: 3.241 2. Derosa G, D’Angelo A, Bonaventura A, Bianchi L, Romano D, Maffioli P. Effects of berberine on lipid profile in subjects with low cardiovascular risk. Expert Opin Biol Ther 2013; 13(4): 475-482. Impact Factor: 3.345 3. Derosa G, Ragonesi PD, Carbone A, Fogari E, D’Angelo A, Cicero AFG, Maffioli P. Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients. Pharmacological Research 2013; 73C: 20-26. Impact Factor: 4.346 4. Derosa G, Cicero AFG, Franzetti IG, Querci F, Carbone A, Piccinni MN, D’Angelo A, Fogari E, Maffioli P. A comparison between sitagliptin or glibenclamide in addition to metformin+pioglitazone on glycemic control and beta-cell function: the triple oral therapy. Diabet Med 2013; 30(7): 846-854. Impact Factor: 3.241 5. Derosa G, Cicero AFG, Carbone A, Querci F, Fogari E, D’Angelo A, Maffioli P. Variation of some inflammatory markers in hypertensive patients after one year of olmesartan/amlodipine single pill combination compared to olmesartan or amlodipine monotherapies. J Am Socs Hyperten 2013; 7(1): 32-39. Impact Factor: 2.835 6. Derosa G, Bonaventura A, Bianchi L, Romano D, D’Angelo A, Fogari E, Maffioli P. Effects of berberis aristata/silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients. J Biol Regul Homeost Agents 2013; 27(3): 709-720. Impact Factor: 5.183 7. Derosa G, Bonaventura A, Bianchi L, Romano D, D’Angelo A, Fogari E, Maffioli P. Berberis aristata/silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients. Expert Opin Biol Ther 2013; 13(11): 1495-1506. Impact Factor: 3.345 8. Derosa G, Cicero AFG, Carbone A, Querci F, Fogari E, D'Angelo A, Maffioli P. Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. Eur J Pharm Sci 2014; 51: 26-33. Impact Factor: 2.987 9. Derosa G, Bonaventura A, Bianchi L, Romano D, Fogari E, D’Angelo A, Maffioli P. Comparison of vildagliptin and glimepiride: effects on glycemic control, fat tolerance, and inflammatory markers in people with type 2 diabetes. Diabet Med 2014; doi: 10.1111/dme.12499. Impact Factor: 3.241 10. Derosa G, Bonaventura A, Bianchi L, Romano D, Fogari E, D'Angelo A, Maffioli P. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. Metabolism 2014; doi: 10.1016/j.metabol.2014.04.008. Impact Factor: 3.096 |